Correction: Exploring the prognostic value of combined assessment of bone marrow plasma cell morphology, Vitamin D, and interleukin-6 in multiple myeloma

• by Ping Huang, Fenping Zhang, Yuchun Lin, Jie Peng, Zesong Yang

• June 10, 2026

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

• by Sandra Susanibar-Adaniya, Benjamin A. Derman, Adam D. Cohen, Dan T. Vogl, Shambavi Richard, Adriana Rossi, Matthew J. Frigualt, Andrew J. Yee, Binod Dhakal, Noffar Bar

• April 28, 2026

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

• by Xinlong Xu, Chang Dong, Jiashuo Guo, Xiaolin Chang, Yu Zhang, Shuting Gou, Liying Xue, Jie Li

• April 29, 2026

Dana-Farber Researchers Presented More Than 50 Research Studies at American Association for Cancer Research Annual Meeting 2026

Select presentations by Dana-Farber faculty include a promising clinical trial chemotherapy and RAS inhibitor combination for pancreatic patients, new research on mapping the tumor microbiome using the presence of microorganisms and encouraging results from a clinical trial for older patients with multiple myeloma precursor conditions.

• April 17, 2026

• 9 min